EXTH-38. ORTHOGONAL IN VIVO MODELS WERE THE SOLE PRECLINICAL PREDICTOR OF CLINICAL EFFICACY IN PHASE 1 TRIALS OF TARGETED THERAPIES FOR GLIOBLASTOMA: RESULTS OF A SYSTEMATIC REVIEW

INTRODUCTION: No drug has improved survival in recurrent glioblastoma despite encouraging activity preclinically. We undertook a systematic review of matched preclinical and Phase 1 trials (P1Ts) of targeted agents to investigate potential preclinical predictors of clinical efficacy. METHODS: We ide...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Gunjur, Ashray, Balasubramanian, Adithya, Hafeez, Umbreen, Menon, Siddharth, Cher, Lawrence, Parakh, Sagun, Gan, Hui
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Preclinical Experimental Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651640/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.392
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars